Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Cash & Current Investments (2020 - 2023)

Terns Pharmaceuticals' Cash & Current Investments history spans 4 years, with the latest figure at $266.6 million for Q3 2023.

  • For Q3 2023, Cash & Current Investments rose 42.35% year-over-year to $266.6 million; the TTM value through Sep 2023 reached $266.6 million, up 42.35%, while the annual FY2022 figure was $283.1 million, 70.57% up from the prior year.
  • Cash & Current Investments reached $266.6 million in Q3 2023 per TERN's latest filing, down from $285.6 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $285.6 million in Q2 2023 to a low of $11.7 million in Q1 2020.
  • Average Cash & Current Investments over 4 years is $162.7 million, with a median of $177.2 million recorded in 2021.
  • Peak YoY movement for Cash & Current Investments: surged 1572.2% in 2021, then fell 24.46% in 2022.
  • A 4-year view of Cash & Current Investments shows it stood at $74.9 million in 2020, then surged by 121.74% to $166.0 million in 2021, then skyrocketed by 70.57% to $283.1 million in 2022, then dropped by 5.83% to $266.6 million in 2023.
  • Per Business Quant, the three most recent readings for TERN's Cash & Current Investments are $266.6 million (Q3 2023), $285.6 million (Q2 2023), and $282.6 million (Q1 2023).